{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:52:57Z","timestamp":1791496377707,"version":"4.3.4"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"DOI":"10.1001\/jamasurg.2019.5410","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T16:01:41Z","timestamp":1578499301000},"page":"e195410","source":"Crossref","is-referenced-by-count":139,"title":["Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer"],"prefix":"10.1001","volume":"155","author":[{"given":"Mehra","family":"Golshan","sequence":"first","affiliation":[{"name":"Department of Surgery, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, German Breast Group, Neu-Isenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Bodo","family":"Huober","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Texas Oncology\u2013Baylor Sammons Cancer Center, US Oncology, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[{"name":"Department of Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"McKee","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maag","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Metzger-Filho","sequence":"additional","affiliation":[{"name":"Department of Surgery, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"Von Minckwitz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles E.","family":"Geyer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Virginia Commonwealth University Massey Cancer Center, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Sikov","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Women and Infants Hospital of Rhode Island, Providence"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Helios Klinikum Berlin-Buch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"issue":"51","key":"soi190082r1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jncimonographs\/lgv008","article-title":"Primary systemic treatment in the management of operable breast cancer: best surgical approach for diagnosis, biological evaluation, and research.","volume":"2015","author":"Barry","year":"2015","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"3","key":"soi190082r2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"soi190082r3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"22","key":"soi190082r4","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","article-title":"Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.","volume":"19","author":"van der Hage","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"soi190082r5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/01.sla.0000234897.38950.5c","article-title":"Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.","volume":"244","author":"Boughey","year":"2006","journal-title":"Ann Surg"},{"issue":"1","key":"soi190082r6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.","volume":"19","author":"Early Breast Cancer Trialists\u2019 Collaborative G","year":"2018","journal-title":"Lancet Oncol"},{"issue":"18","key":"soi190082r7","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"issue":"8","key":"soi190082r8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"soi190082r9","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"soi190082r10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial.","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"soi190082r11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"soi190082r12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"soi190082r13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of veliparib-carboplatin treatment in breast cancer.","volume":"375","author":"Rugo","year":"2016","journal-title":"N Engl J Med"},{"issue":"9938","key":"soi190082r14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"soi190082r15","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"soi190082r16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"soi190082r17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.2017.35.15_suppl.520","article-title":"Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).","volume":"35","author":"Geyer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"soi190082r18","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1245\/s10434-015-4502-7","article-title":"Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?","volume":"22","author":"Jochelson","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"soi190082r19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/SLA.0000000000001417","article-title":"Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).","volume":"262","author":"Golshan","year":"2015","journal-title":"Ann Surg"},{"issue":"4","key":"soi190082r20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","article-title":"Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.","volume":"260","author":"Boughey","year":"2014","journal-title":"Ann Surg"},{"issue":"9","key":"soi190082r21","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"issue":"8","key":"soi190082r22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bmjopen-2013-003179","article-title":"Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics.","volume":"3","author":"Neuburger","year":"2013","journal-title":"BMJ Open"},{"issue":"6","key":"soi190082r23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamasurg.2013.5689","article-title":"Social and clinical determinants of contralateral prophylactic mastectomy.","volume":"149","author":"Hawley","year":"2014","journal-title":"JAMA Surg"},{"issue":"6","key":"soi190082r24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/tbj.2016.22.issue-6","article-title":"Differences between breast conservation-eligible patients and unilateral mastectomy patients in choosing contralateral prophylactic mastectomies.","volume":"22","author":"Sabel","year":"2016","journal-title":"Breast J"},{"issue":"20","key":"soi190082r25","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","article-title":"Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer.","volume":"35","author":"Kurian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"soi190082r26","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/cncr.28050","article-title":"Trends in immediate breast reconstruction across insurance groups after enactment of breast cancer legislation.","volume":"119","author":"Yang","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"soi190082r27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer.","volume":"112","author":"Alderman","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"soi190082r28","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1245\/s10434-015-4572-6","article-title":"Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer.","volume":"22","author":"Rosenberg","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"soi190082r29","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1245\/s10434-011-2080-x","article-title":"Which eligible breast conservation patients choose mastectomy in the setting of newly diagnosed breast cancer?","volume":"19","author":"Adkisson","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"soi190082r30","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1245\/s10434-014-3903-3","article-title":"Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy.","volume":"21","author":"Eck","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"soi190082r31","doi-asserted-by":"publisher","first-page":"W225","DOI":"10.2214\/AJR.16.17125","article-title":"Predictive clinicopathologic and dynamic contrast-enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple-negative breast cancer.","volume":"208","author":"Eom","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"soi190082r32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.","volume":"105","author":"Marinovich","year":"2013","journal-title":"J Natl Cancer Inst"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2758160\/jamasurgery_golshan_2020_oi_190082_1615313183.75808.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T16:07:36Z","timestamp":1615392456000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2758160"}},"subtitle":["Surgical Results From the BrighTNess Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2019.5410","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,18]]}}}